Cullinan Therapeutics Inc
CGEM
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.33B
Close$
$1.45
93.5% downside
Current Fair Value
93.5% downsideOvervalued by 93.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.33 Billion |
|---|---|
| Enterprise Value | $1.26 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.72 |
| Beta | -0.01 |
| Outstanding Shares | 61,493,000 |
Return
| Return on Equity | -63.62% |
|---|---|
| Return on Assets | -56.27% |
| Return on Invested Capital | -69.08% |
Valuation & Multiples
| P/E Ratio | -6.44 |
|---|---|
| PEG | 27.59 |
| Price to Sales | - |
| Price to Book Ratio | 4.47 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -5.63 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$3.67 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.85
Average shareholder expectationRevenue Estimate
$2.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7454▲ 45.60% |
|---|---|
| Total Calls | 185,000▼ 8.78% |
| Total Puts | 137,900▲ 134.92% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 122.99%▲ 12.25% |
|---|---|
| Total Invested | $1.35B▲ 45.26% |
| Investors Holding | 193▲ 16.00% |
ESG Score
No data
About Cullinan Oncology Inc
24 employeesCullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build a pi...